Multiple myeloma (MM), a plasma cell disease, was newly diagnosed in an estimated 24 280 individuals in 2016 in the United States ([@bib19]). Besides well-established risk factors, such as male sex, older age, African ancestry, and a family history of haematological malignancies ([@bib2]), obesity has been shown to increase MM risk ([@bib20]). The association between obesity and MM may be attributable in part to altered levels of various adipokines (e.g., adiponectin, leptin, and resistin) secreted by adipose tissue ([@bib6]). We have recently shown that the risk of MM is increased for individuals with low pre-diagnosis circulating levels of adiponectin ([@bib11]), but not of leptin ([@bib12]). The potential role of resistin in MM development is poorly understood. An increased risk of MM for individuals with low serum levels of resistin was observed by one small hospital-based case--control study (73 MM cases and 73 controls) ([@bib6]). To our knowledge, the relationship between resistin and MM has not been evaluated prospectively. Using a nested case--control study involving three cohorts participating in the MM cohort consortium, we investigated whether pre-diagnosis circulating levels of resistin were associated with future MM risk.

Materials and methods
=====================

Cases (*n*=178) and controls (*n*=358) were selected from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), the Cancer Prevention Study II (CPS-II), and the Melbourne Collaborative Cohort Study (MCCS) ([@bib1]; [@bib4]; [@bib9]). Participating cohorts received Institutional Review Board approval from their respective institutions. We selected cases with a primary incident diagnosis of MM (ICDA=203; ICD-O-2-M=9731, 9732, and 9830; or ICD-O-3-M=9731--9734) and a stored blood sample collected ⩾3 months before MM diagnosis. Controls with no history of cancer were individually matched to cases based on cohort of origin, birth year (±12 months), sex, type of blood sample (serum, plasma-heparin, and plasma-EDTA), date of blood collection (±2 months), and fasting status at blood draw with a 2 : 1 ratio as previously described ([@bib3]; [@bib11]). All of the cases and controls included in this investigation were non-Hispanic whites.

Circulating levels of resistin were measured in duplicate by ELISA (Human Resistin Quantikine ELISA by R&D Systems, Inc., Minneapolis, MN, USA). Assays were performed in the laboratory of MNP at McGill University. The lower limit of detection was 0.156 ng ml^−1^. Samples from MM patients and their matched controls were analysed in the same batch, and blinded quality control (QC) replicates were included in each batch as previously described ([@bib11]). The overall intraclass correlation coefficient was 0.86, and the coefficient of variation for pooled QC specimens was 6.1%, with no evidence of laboratory drift across cohorts.

We used the Wilcoxon rank-sum test to assess differences in resistin levels between cases and controls. For our main analyses, we performed cohort- and sex-specific corrections of resistin values to reduce the impact of cohort-related variability, and to account for differences between men and women within and across the participating studies ([@bib3]; [@bib11]) ([Supplementary Methods](#sup1){ref-type="supplementary-material"}). Odds ratios (ORs) and 95% confidence intervals (95% CIs) for risk of MM were computed using conditional logistic regression models with levels of resistin categorised into quartiles based on the distribution among controls. We performed analyses stratified by sex, time to MM diagnosis, and age at sample collection using conditional logistic regression models, and analyses stratified by BMI categories using unconditional logistic regression models adjusted for matching factors. Multiplicative interaction was assessed using Wald tests. Study-specific ORs and 95% CIs were estimated comparing resistin levels above and below the median (based on the distribution in controls); we conducted a meta-analysis using both fixed and random effects models, and assessed heterogeneity across cohorts using the Cochran *Q*-test and the *I*^2^ statistic. For all analyses, findings were considered statistically significant if the two-sided *P*-value was \<0.05.

Results
=======

Cases and controls had similar distributions of sex, age at the blood draw, and type of blood sample ([Table 1](#tbl1){ref-type="table"}). Cohort- and sex-corrected resistin levels were somewhat lower among cases compared with controls; these differences were statistically significant among men (*P*=0.006, Wilcoxon rank-sum test) but not among women (*P*=0.22). Levels of resistin and total adiponectin (measured previously) were not correlated among cases or controls (Spearman's correlation coefficients of −0.07 and 0.09, respectively; *P*⩾0.1). In multivariate analyses of the pooled controls, circulating levels of resistin were higher among men compared with women, but were not associated with age or BMI ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Higher resistin levels were weakly associated with a reduced risk of MM in overall analyses, although the observed associations were not statistically significant ([Table 2](#tbl2){ref-type="table"}). Findings were similar after adjusting for BMI and adiponectin levels. Among a subset of participants from the ATBC and MCCS cohorts with available data on markers related to IGF-1 and interleukin (IL)-6 pathways ([@bib3]), we found that results were essentially unchanged after adjustment for these other analytes (data not shown). Among men, we observed a statistically significant reduced risk of MM among those with higher levels of resistin (ORs of 0.44 (95% CI 0.24--0.83) and 0.54 (0.29--0.99) for the third and fourth quartiles, respectively, *vs* the lowest quartile; *P*~trend~=0.026). This association remained after adjusting for BMI and adiponectin levels (data not shown). In contrast, resistin levels were not associated with MM risk among women (*P*~interaction~=0.12). In other stratified analyses, we did not observe statistically significant differences in the ORs across strata for time to MM diagnosis, BMI category, or age at blood collection. Our main findings were essentially unchanged after excluding high outlying resistin levels and when quartiles were based on the overall distribution of resistin levels among controls rather than the cohort- and sex-corrected levels.

Cohort- and sex-specific results are shown in [Figure 1](#fig1){ref-type="fig"}. Among men, there was some evidence of heterogeneity across cohorts (*I*^2^=62.3%, *P*=0.071). The association was strongest among men in the MCCS (OR 0.12, 95% CI 0.026--0.53), although non-significant inverse associations were also observed among men in the other cohorts (ORs of 0.63 (0.30--1.34) and 0.79 (0.42--1.48) in CPS-II and ATBC, respectively). Among women, ORs were elevated but not statistically significant in both CPS-II and MCCS.

Discussion
==========

This study is, to our knowledge, the first prospective investigation of circulating levels of resistin and risk of MM. Our findings suggest that high pre-diagnosis circulating resistin levels are associated with a reduced future risk of MM development, in particular among men. These results are consistent with findings from a prior hospital-based case--control study ([@bib6]). Although we did not find evidence of an association among women, our investigation included relatively few female MM cases and thus we had limited statistical power for this subgroup analysis. Our findings may also reflect true differences by sex in the biological activity of resistin due to interaction with sex or metabolic hormones or other inflammatory markers that are differentially expressed in men and women ([@bib7]). We also observed a somewhat stronger association during the time period closer to MM diagnosis, which may reflect altered resistin expression related to onset or progression of monoclonal gammopathy of undetermined significance.

Resistin increases nuclear factor kappa B-related monocyte expression of pro-inflammatory cytokines such as IL-6 ([@bib22]; [@bib14]). Thus, the observed increased risk of MM in males with lower levels of resistin might reflect a compensatory effect of resistin or a negative feedback loop following the production of IL-6 and/or other cytokines with known effects on proliferation and survival of MM cells ([@bib6]). Alternatively, previous studies have shown that TNF-*α* decreases resistin secretion in murine models ([@bib16]). If TNF-*α*, a well-characterised pro-inflammatory cytokine that stimulates MM cell proliferation ([@bib10]), also acts as a negative regulator of resistin in humans, this action may explain the observed inverse association between pre-diagnosis resistin levels and MM risk. This hypothesis is corroborated by increased resistin levels in MM patients after treatment with thalidomide, a TNF-*α* inhibitor ([@bib17]).

Resistin deregulation in obesity-related inflammatory conditions may also result from altered expression by non-adipocyte inflammatory cells, such as macrophages, in adipose tissue ([@bib15]; [@bib5]). While some studies have observed elevated levels of resistin among individuals with higher BMI or visceral fat area ([@bib23]; [@bib17]), other studies found no association ([@bib13]; [@bib7]). The lack of association of resistin with BMI in our study suggests that resistin may influence MM risk through other inflammatory processes. Notably, resistin is also highly expressed in the bone marrow (BM) where it is secreted by osteoclasts and osteoblasts, as well as by monocytes and macrophages ([@bib15]). Resistin activates osteoclastogenesis and promotes osteoblast proliferation ([@bib21]), which suggests a role for resistin in bone remodelling. Considering the interplay between the BM microenvironment and the proliferation of MM cells ([@bib8]), impaired resistin expression in the BM niche may induce changes that are favourable to the proliferation of MM cells, which might explain the observed inverse association between resistin and MM risk. Functional analyses in BM tissue could help to clarify the role of resistin and other adipokines in MM pathogenesis.

The strengths of our study include its prospective design and the pooling of data across three cohorts. Limitations include the lack of detailed information on clinical characteristics of MM at diagnosis, as well as information on family history of lymphohaematopoietic malignancies. Given that having a family history of these relatively rare malignancies is uncommon in the general population ([@bib18]), the potential for confounding by family history is likely to be minimal. However, further investigation in family-based studies and other studies with detailed clinical records may be informative. Finally, although this study is the largest to date that has evaluated the association between resistin and MM, we had limited statistical power for analyses restricted to women, as well as for the cohort-specific and other stratified analyses. Extending this investigation to other prospective cohorts is required to confirm our findings and to better elucidate the differences by sex in the relationship between resistin and MM.
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###### 

Click here for additional data file.

![**Cohort-specific and meta-analysis summary ORs and 95% CIs for the association between circulating resistin levels (above *vs* below the median) and MM risk among men (upper panel) and women (lower panel).**](bjc2017282f1){#fig1}

###### Selected characteristics of cases and controls

  **Characteristic**                                                    **Cases**[a](#t1-fn2){ref-type="fn"}       **Controls**[a](#t1-fn2){ref-type="fn"}
  ---------------------------------------------------------------- ---------------------------------------------- -----------------------------------------
  Patients                                                                           178 (100)                                    358 (100)
  Cohort                                                                                                                               
   ATBC                                                                              59 (33.2)                                   117 (32.7)
   CPS-II                                                                            67 (37.6)                                   135 (37.7)
   MCCS                                                                              52 (29.2)                                   106 (29.6)
  Sex                                                                                                                                  
   Female                                                                            49 (27.5)                                   100 (27.9)
   Male                                                                              129 (72.5)                                  258 (72.1)
  Mean (s.d.) age at blood draw                                                      63.0 (7.8)                                  63.0 (7.8)
  Mean (s.d.) BMI at blood draw, kg/m^2^                                             26.9 (4.0)                                  26.5 (4.2)
  Type of blood sample                                                                                                                 
   EDTA                                                                              67 (37.6)                                   135 (37.7)
   Heparin plasma                                                                    52 (29.2)                                   106 (29.6)
   Serum                                                                             59 (33.2)                                   117 (32.7)
  Time from blood draw to diagnosis                                                                                                    
   \<7 years                                                                         85 (47.8)                                         
   ⩾7 years                                                                          93 (52.3)                                         
  Median resistin concentration[b](#t1-fn3){ref-type="fn"} (IQR)                                                                       
   Overall                                                                       5.47 (4.08--7.11)                            5.82 (4.47--7.37)
   Female                                                                        6.24 (5.11--8.44)                            5.88 (4.48--7.66)
   Male                                                             5.20 (3.93--6.46)[c](#t1-fn4){ref-type="fn"}              5.82 (4.44--7.33)

Abbreviations: ATBC=Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BMI=body mass index; CPS-II=the Cancer Prevention Study II; IQR=interquartile range; MCCS=Melbourne Collaborative Cohort Study.

Reported as *N* (%) unless otherwise noted.

On the basis of corrected resistin levels in ng ml^−1^ ([Supplementary Methods](#sup1){ref-type="supplementary-material"}).

Wilcoxon two-sample test *P*=0.006.

###### Circulating resistin levels and risk of MM, overall and stratified by selected characteristics

                                               **Quartile (Q)**                                                                                                  
  -------------------------------------------- ------------------ ----------- ---- ------------------- ---- ------------------- ---- -------------------- ------ ------
  Crude                                        55                 1.0 (ref)   48   0.87 (0.53--1.44)   33   0.61 (0.36--1.03)   42   0.75 (0.45--1.25)    0.20    
  Adjusted for BMI                             54                 1.0 (ref)   48   0.87 (0.52--1.46)   32   0.60 (0.35--1.02)   41   0.76 (0.45--1.29)    0.24    
  Adjusted for BMI and adiponectin             54                 1.0 (ref)   48   0.86 (0.51--1.43)   32   0.59 (0.35--1.01)   41   0.76 (0.45--1.29)    0.24    
  By sex                                                                                                                                                          
   Female                                      9                  1.0 (ref)   11   1.27 (0.44--3.64)   12   1.56 (0.55--4.45)   17   1.82 (0.66--5.00)    0.23    
   Male                                        46                 1.0 (ref)   37   0.77 (0.43--1.38)   21   0.44 (0.24--0.83)   25   0.54 (0.29--0.995)   0.03   0.12
  By time to MM diagnosis                                                                                                                                         
   \<7 years                                   28                 1.0 (ref)   20   0.63 (0.29--1.37)   14   0.41 (0.18--0.90)   23   0.61 (0.30--1.25)    0.21    
   ⩾7 years                                    27                 1.0 (ref)   28   1.14 (0.58--2.26)   19   0.92 (0.45--1.87)   19   0.87 (0.41--1.86)    0.61   0.47
  By BMI_category[b](#t2-fn4){ref-type="fn"}                                                                                                                      
   \<25 kg m^−2^                               23                 1.0 (ref)   12   0.59 (0.25--1.36)   13   0.68(0.29--1.57)    13   0.61 (0.27--1.40)    0.30    
   25--29.9 kg m^−2^                           19                 1.0 (ref)   26   0.98 (0.44--2.18)   17   0.60 (0.26--1.42)   16   0.62 (0.26--1.52)    0.20    
   ⩾30 kg m^−2^                                12                 1.0 (ref)   10   1.31 (0.43--3.95)   2    0.23 (0.04--1.21)   12   1.47 (0.46--4.64)    0.91   0.45
  By age at blood draw                                                                                                                                            
   \<65 years                                  34                 1.0 (ref)   31   0.86 (0.45--1.64)   17   0.55 (0.27--1.13)   18   0.61 (0.29--1.26)    0.12    
   ⩾65 years                                   21                 1.0 (ref)   17   0.87 (0.38--1.97)   16   0.64 (0.29--1.41)   24   0.89 (0.42--1.91)    0.78   0.76

Abbreviations: BMI=body mass index; CI=confidence interval; MM=multiple myeloma; OR=odds ratio; *P*~int~=*P*~interaction~; ref=reference.

Odds ratios and 95% CI were estimated using conditional logistic regression models, unless otherwise noted. Quartile cut-off points were defined on the basis of the distribution of cohort- and sex-adjusted resistin levels among controls, as follows: Q1⩽4.59 ng ml^−1^, Q2 4.60--5.82 ng ml^−1^, Q3 5.83--7.37 ng ml^−1^, and Q4⩾7.38 ng ml^−1^.

Tests of multiplicative interaction were based on the same models as those used for the stratified analyses and were performed using Wald tests.

Unconditional logistic regression adjusted for cohort, age, sex and fasting status.
